Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COR Stock Forecast 2026-2027
$312.39
Current Price
$59.98B
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to COR Price Targets
+43.1%
To High Target of $447.00
+30.4%
To Median Target of $407.50
+8.8%
To Low Target of $340.00
COR Price Momentum
-1.6%
1 Week Change
-4.4%
1 Month Change
+9.1%
1 Year Change
-7.5%
Year-to-Date Change
-17.3%
From 52W High of $377.54
+15.3%
From 52W Low of $271.00
📊 TOP ANALYST CALLS
Did COR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cencora is one of their latest high-conviction picks.
Latest COR Stock Price Targets & Analyst Predictions
Based on our analysis of 32 Wall Street analysts, COR has a bullish consensus with a median price target of $407.50 (ranging from $340.00 to $447.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $312.39, the median forecast implies a 30.4% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Steven Valiquette at Mizuho, suggesting a 8.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COR Analyst Ratings
11
Buy
2
Hold
0
Sell
COR Price Target Range
Low
$340.00
Average
$407.50
High
$447.00
Current: $312.39
Latest COR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | Evercore ISI Group | John Belton | Outperform | Maintains | $360.00 |
| Feb 13, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $425.00 |
| Feb 10, 2026 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $429.00 |
| Feb 10, 2026 | JP Morgan | Lisa Gill | Overweight | Maintains | $419.00 |
| Feb 5, 2026 | Evercore ISI Group | John Belton | Outperform | Maintains | $420.00 |
| Jan 29, 2026 | Morgan Stanley | Erin Wright | Overweight | Upgrade | $400.00 |
| Jan 22, 2026 | Jefferies | Brian Tanquilut | Buy | Upgrade | $440.00 |
| Jan 5, 2026 | B of A Securities | Michael Funk | Neutral | Maintains | $360.00 |
| Dec 9, 2025 | Barclays | Glen Santangelo | Overweight | Initiates | $400.00 |
| Nov 11, 2025 | JP Morgan | Lisa Gill | Overweight | Maintains | $417.00 |
| Nov 11, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $405.00 |
| Nov 10, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $400.00 |
| Nov 7, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $415.00 |
| Nov 6, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $380.00 |
| Nov 6, 2025 | Baird | David Rodgers | Outperform | Maintains | $395.00 |
| Oct 30, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $340.00 |
| Oct 27, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $380.00 |
| Oct 16, 2025 | Mizuho | Steven Valiquette | Outperform | Maintains | $334.00 |
| Aug 13, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $354.00 |
| Jul 16, 2025 | Morgan Stanley | Erin Wright | Equal-Weight | Maintains | $330.00 |
Cencora, Inc. (COR) Competitors
The following stocks are similar to Cencora based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cencora, Inc. (COR) Financial Data
Cencora, Inc. has a market capitalization of $59.98B with a P/E ratio of 37.5x. The company generates $325.78B in trailing twelve-month revenue with a 0.5% profit margin.
Revenue growth is +5.5% quarter-over-quarter, while maintaining an operating margin of +1.2% and return on equity of +133.5%.
Valuation Metrics
Market Cap
$59.98B
Enterprise Value
$69.11B
P/E Ratio
37.5x
PEG Ratio
2.6x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+5.5%
Gross Margin
+3.6%
Operating Margin
+1.2%
Net Margin
+0.5%
EPS Growth
+14.5%
Financial Health
Cash/Price Ratio
+2.9%
Current Ratio
0.9x
Debt/Equity
472.6x
ROE
+133.5%
ROA
+3.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cencora, Inc. (COR) Business Model
About Cencora, Inc.
What They Do
Global pharmaceutical solutions and distribution company.
Business Model
Cencora, Inc. generates revenue by distributing pharmaceuticals and healthcare products to a wide range of healthcare providers, including hospitals, pharmacies, and clinics. Additionally, it offers consulting services and patient services, creating value through innovative partnerships that enhance product access and operational efficiency in healthcare.
Additional Information
With operations in over 50 countries, Cencora supports both human and animal health, focusing on logistics and supply chain solutions that facilitate the delivery of life-changing therapies. The company is headquartered in Conshohocken, Pennsylvania, and is committed to improving healthcare delivery and outcomes.
Company Information
Sector
Healthcare
Industry
Medical Distribution
Employees
47,000
CEO
Dr. Robert P. Mauch Ph.D., PharmD
Country
United States
IPO Year
2023
Website
www.cencora.comCencora, Inc. (COR) Latest News & Analysis
Latest News
Quick Summary
Cencora (COR) retains its 2025 buy rating, supported by strong fundamentals, global reach, and a compelling dividend track record despite recent price declines.
Why It Matters
Cencora's reaffirmed buy rating highlights strong fundamentals and consistent dividend growth, signaling resilience and potential for long-term investment value despite recent price declines.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Cencora, Inc. (NYSE: COR) will release its Q2 Fiscal 2026 results on May 6, 2026, before market open, followed by a conference call at 8:30 a.m. ET with key executives.
Why It Matters
Cencora's upcoming earnings report and conference call may influence stock performance, providing insights into its financial health and future outlook, impacting investor sentiment and decision-making.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cencora plans to acquire EyeSouth Partners' retina business for $1.1 billion, enhancing its eye care division.
Why It Matters
Cencora's $1.1 billion acquisition of EyeSouth Partners enhances its eye care portfolio, potentially driving revenue growth and market share, which could positively impact stock performance.
Source: Reuters
Market Sentiment:
Positive
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business
30 days ago
Quick Summary
Cencora, Inc. (NYSE: COR) has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, enhancing its Retina Consultants of America network.
Why It Matters
Cencora's $1.1 billion acquisition of EyeSouth's retina business enhances its market position in ophthalmology, potentially driving revenue growth and expanding its physician network.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cencora is acquiring EyeSouth's retina business for $1.1 billion, enhancing its RCA platform and expanding its presence in the eye care market.
Why It Matters
Cencora's $1.1 billion acquisition of EyeSouth's retina business enhances its position in the lucrative eye care sector, likely boosting future revenue and market share.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Cencora reports strong U.S. growth and an enhanced MSO strategy, raising its outlook. However, competition and customer losses pose significant risks.
Why It Matters
Cencora's U.S. growth and optimistic outlook suggest potential for profitability, but ongoing competition and customer retention issues could impact future performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About COR Stock
What is Cencora, Inc.'s (COR) stock forecast for 2026?
Based on our analysis of 32 Wall Street analysts, Cencora, Inc. (COR) has a median price target of $407.50. The highest price target is $447.00 and the lowest is $340.00.
Is COR stock a good investment in 2026?
According to current analyst ratings, COR has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $312.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COR stock?
Wall Street analysts predict COR stock could reach $407.50 in the next 12 months. This represents a 30.4% increase from the current price of $312.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cencora, Inc.'s business model?
Cencora, Inc. generates revenue by distributing pharmaceuticals and healthcare products to a wide range of healthcare providers, including hospitals, pharmacies, and clinics. Additionally, it offers consulting services and patient services, creating value through innovative partnerships that enhance product access and operational efficiency in healthcare.
What is the highest forecasted price for COR Cencora, Inc.?
The highest price target for COR is $447.00 from at , which represents a 43.1% increase from the current price of $312.39.
What is the lowest forecasted price for COR Cencora, Inc.?
The lowest price target for COR is $340.00 from Steven Valiquette at Mizuho, which represents a 8.8% increase from the current price of $312.39.
What is the overall COR consensus from analysts for Cencora, Inc.?
The overall analyst consensus for COR is bullish. Out of 32 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $407.50.
How accurate are COR stock price projections?
Stock price projections, including those for Cencora, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 9:07 PM UTC